239 related articles for article (PubMed ID: 24657487)
1. B7-H4 as a potential target for immunotherapy for gynecologic cancers: a closer look.
Smith JB; Stashwick C; Powell DJ
Gynecol Oncol; 2014 Jul; 134(1):181-189. PubMed ID: 24657487
[TBL] [Abstract][Full Text] [Related]
2. Novel recombinant human b7-h4 antibodies overcome tumoral immune escape to potentiate T-cell antitumor responses.
Dangaj D; Lanitis E; Zhao A; Joshi S; Cheng Y; Sandaltzopoulos R; Ra HJ; Danet-Desnoyers G; Powell DJ; Scholler N
Cancer Res; 2013 Aug; 73(15):4820-9. PubMed ID: 23722540
[TBL] [Abstract][Full Text] [Related]
3. Development of a novel anti-B7-H4 antibody enhances anti-tumor immune response of human T cells.
Miao G; Sun X
Biomed Pharmacother; 2021 Sep; 141():111913. PubMed ID: 34328096
[TBL] [Abstract][Full Text] [Related]
4. B7-H4 is Inversely Correlated With T-Cell Infiltration in Clear Cell but Not Serous or Endometrioid Ovarian Cancer.
Pagnotti GM; Atkinson RM; Romeiser J; Akalin A; Korman MB; Shroyer KR
Appl Immunohistochem Mol Morphol; 2019 Aug; 27(7):515-522. PubMed ID: 29189263
[TBL] [Abstract][Full Text] [Related]
5. Could B7-H4 serve as a target to activate anti-cancer immunity?
Wang L; Heng X; Lu Y; Cai Z; Yi Q; Che F
Int Immunopharmacol; 2016 Sep; 38():97-103. PubMed ID: 27258187
[TBL] [Abstract][Full Text] [Related]
6. B7-H4 expression in ovarian serous carcinoma: a study of 306 cases.
Liang L; Jiang Y; Chen JS; Niu N; Piao J; Ning J; Zu Y; Zhang J; Liu J
Hum Pathol; 2016 Nov; 57():1-6. PubMed ID: 27349304
[TBL] [Abstract][Full Text] [Related]
7. Molecular Pathways: Evaluating the Potential for B7-H4 as an Immunoregulatory Target.
MacGregor HL; Ohashi PS
Clin Cancer Res; 2017 Jun; 23(12):2934-2941. PubMed ID: 28325750
[TBL] [Abstract][Full Text] [Related]
8. Potential targeting of B7-H4 for the treatment of cancer.
Podojil JR; Miller SD
Immunol Rev; 2017 Mar; 276(1):40-51. PubMed ID: 28258701
[TBL] [Abstract][Full Text] [Related]
9. Tumor Regression and Delayed Onset Toxicity Following B7-H4 CAR T Cell Therapy.
Smith JB; Lanitis E; Dangaj D; Buza E; Poussin M; Stashwick C; Scholler N; Powell DJ
Mol Ther; 2016 Nov; 24(11):1987-1999. PubMed ID: 27439899
[TBL] [Abstract][Full Text] [Related]
10. Enhanced B7-H4 expression in gliomas with low PD-L1 expression identifies super-cold tumors.
Chen D; Li G; Ji C; Lu Q; Qi Y; Tang C; Xiong J; Hu J; Yasar FBA; Zhang Y; Hoon DSB; Yao Y; Zhou L
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32457124
[TBL] [Abstract][Full Text] [Related]
11. Unstable B7-H4 cell surface expression and T-cell redirection as a means of cancer therapy.
Iizuka A; Kondou R; Nonomura C; Ashizawa T; Ohshima K; Kusuhara M; Isaka M; Ohde Y; Yamaguchi K; Akiyama Y
Oncol Rep; 2016 Nov; 36(5):2625-2632. PubMed ID: 27632942
[TBL] [Abstract][Full Text] [Related]
12. Expression of B7-H4 and IDO1 is associated with drug resistance and poor prognosis in high-grade serous ovarian carcinomas.
Niu N; Shen W; Zhong Y; Bast RC; Jazaeri A; Sood AK; Liu J
Hum Pathol; 2021 Jul; 113():20-27. PubMed ID: 33887301
[TBL] [Abstract][Full Text] [Related]
13. Pharmacologic Suppression of B7-H4 Glycosylation Restores Antitumor Immunity in Immune-Cold Breast Cancers.
Song X; Zhou Z; Li H; Xue Y; Lu X; Bahar I; Kepp O; Hung MC; Kroemer G; Wan Y
Cancer Discov; 2020 Dec; 10(12):1872-1893. PubMed ID: 32938586
[TBL] [Abstract][Full Text] [Related]
14. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma.
Kryczek I; Zou L; Rodriguez P; Zhu G; Wei S; Mottram P; Brumlik M; Cheng P; Curiel T; Myers L; Lackner A; Alvarez X; Ochoa A; Chen L; Zou W
J Exp Med; 2006 Apr; 203(4):871-81. PubMed ID: 16606666
[TBL] [Abstract][Full Text] [Related]
15. Synergistic effects of host B7-H4 deficiency and gemcitabine treatment on tumor regression and anti-tumor T cell immunity in a mouse model.
Leung J; St-Onge P; Stagg J; Suh WK
Cancer Immunol Immunother; 2017 Apr; 66(4):491-502. PubMed ID: 28074226
[TBL] [Abstract][Full Text] [Related]
16. B7-H4 expression by nonhematopoietic cells in the tumor microenvironment promotes antitumor immunity.
Rahbar R; Lin A; Ghazarian M; Yau HL; Paramathas S; Lang PA; Schildknecht A; Elford AR; Garcia-Batres C; Martin B; Berman HK; Leong WL; McCready DR; Reedijk M; Done SJ; Miller N; Youngson B; Suh WK; Mak TW; Ohashi PS
Cancer Immunol Res; 2015 Feb; 3(2):184-95. PubMed ID: 25527357
[TBL] [Abstract][Full Text] [Related]
17. B7-H4's role "beyond the tumor".
Yu N; Li X; Zheng S; Li X
Inflammation; 2013 Aug; 36(4):941-7. PubMed ID: 23605559
[TBL] [Abstract][Full Text] [Related]
18. Host B7-H4 regulates antitumor T cell responses through inhibition of myeloid-derived suppressor cells in a 4T1 tumor transplantation model.
Leung J; Suh WK
J Immunol; 2013 Jun; 190(12):6651-61. PubMed ID: 23686485
[TBL] [Abstract][Full Text] [Related]
19. Does B7-H4 expression correlate with clinicopathologic characteristics and survival in ovarian cancer?: A systematic review and PRISMA-compliant meta-analysis.
Ye Y; Wang JJ; Li SL; Wang SY; Jing FH
Medicine (Baltimore); 2018 Aug; 97(32):e11821. PubMed ID: 30095655
[TBL] [Abstract][Full Text] [Related]
20. Isolation and Validation of Anti-B7-H4 scFvs from an Ovarian Cancer scFv Yeast-Display Library.
Dangaj D; Scholler N
Methods Mol Biol; 2015; 1319():37-49. PubMed ID: 26060068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
